Novo Nordisk details heart benefits of weight loss drug


New Nordisk

hapabapa/iStock Editorial via Getty Images

Novo Nordisk (NVO) announced Saturday that its FDA-approved weight loss therapy Wegovy, also known as semaglutide, led to cardiovascular benefits irrespective of age, gender, ethnicity, and obesity level in a Phase 3 trial.

In August, the Danish drugmaker said that the

Source link

Leave A Reply

Your email address will not be published.